GLP-1 compounders find loophole in FDA crackdown, study suggests

Compounding pharmacies have found a way to navigate the FDA's restrictions on copying approved GLP-1 medications like semaglutide and tirzepatide by making minor adjustments to their formulations, as revealed by a recent study in JAMA Health Forum. This move comes amid a surge in demand for these drugs, prompting the FDA to place them on its shortage list. The loophole raises concerns about the integrity and safety of compounded medications, highlighting the ongoing struggle to balance regulation with patient needs in a rapidly evolving healthcare market.